Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

MNKDBullishAnalyst Ratingnews

High materiality7/10

Chardan Initiates MannKind Coverage with Buy and $10 Target

Oct 19, 2026, 10:29 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Fresh Buy rating and a high PT create upside expectations, especially given MNKD's low price around $3.04; similar past initiations have pressured shorts to cover and attracted new buyers.

AI summary

What happened, with direct paths to the underlying reporting

Chardan Capital initiated coverage on MannKind Corp (MNKD) with a Buy rating and a $10 price target, signaling potential upside from its portfolio. MNKD traded around $3.04 as of Friday, implying substantial upside if the new coverage shifts sentiment and attracts buyers. The catalyst is analyst visibility rather than new clinical data, suggesting a likely short-term re-rating rather than an immediate fundamental upgrade.

Chardan starts MNKD coverage with Buy; PT $10.
MNKD closed at $3.04 on Friday.
Analyst activity on MNKD may spark near-term upside.
Other initiations mentioned: RSI, NWCL, HDRN, AIB.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Chardan Initiates MannKind Coverage with Buy and $10 Target

MannKind inks ROSE-010 GLP-1 license with Rose Pharma; shares dip

MannKind FDA Approves Furoscix ReadyFlow; Private Financing Supports CVR Payment

FDA expands MNKD pediatric indication for inhaled insulin